Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | GRIN2B | Q13224 | 12/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.45 |
| ▸ | FAAH | O00519 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL948517 | 0.79 | SMN1; SMN2 (0.50) | SMN1; SMN2NPC1RAB9AGRIN2BCYP2C19 | |
| SCHEMBL2855618 | 0.76 | SMN1; SMN2 (0.60) | SMN1; SMN2NPC1RAB9AGRIN2BCYP2C19 | |
| SCHEMBL947735 | 0.76 | SMN1; SMN2 (0.48) | SMN1; SMN2NPC1RAB9AGRIN2BCYP2C19 | |
| SCHEMBL7399416 | 0.76 | SMN1; SMN2 (0.65) | SMN1; SMN2NPC1RAB9AGRIN2BCYP2C19 | |
| SCHEMBL5493772 | 0.76 | SMN1; SMN2 (0.58) | SMN1; SMN2NPC1RAB9AGRIN2BCYP2C19 | |
| SCHEMBL2851491 | 0.75 | SMN1; SMN2 (0.57) | SMN1; SMN2NPC1RAB9AGRIN2BCYP2C19 | |
| SCHEMBL5866405 | 0.75 | SMN1; SMN2 (0.57) | SMN1; SMN2NPC1RAB9AGRIN2BCYP2C19 | |
| SCHEMBL950010 | 0.74 | F2 (0.49) | SMN1; SMN2NPC1RAB9AGRIN2BCYP2C19 | |
| SCHEMBL14334656 | 0.73 | SMN1; SMN2 (0.58) | SMN1; SMN2NPC1RAB9AGRIN2BCYP2C19 | |
| SCHEMBL31435518 | 0.73 | SMN1; SMN2 (0.58) | SMN1; SMN2NPC1RAB9AGRIN2BCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110009389-A1 | IMIDAZOLE DERIVATIVE, THEIR PRODUCTION AND USE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-01-13 | — | — | US | disclosed |
| US-20070004736-A1 | Imidazole derivative, process for producing the same, and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-01-04 | — | — | US | disclosed |
| EP-1564213-A1 | IMIDAZOLE DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE | Takeda Pharmaceutical Company Limited (JP) | 2005-08-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004736-A1 | Imidazole derivative, process for producing the same, and use | HRH4, F2, HRH2 | SMN1; SMN2 3368/4885NPC1 2889/4885RAB9A 3665/4885 |
| US-20110009389-A1 | IMIDAZOLE DERIVATIVE, THEIR PRODUCTION AND USE | F2, H1-3, CYC1 | SMN1; SMN2 3635/4885NPC1 2969/4885RAB9A 3699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.